Based in Rockville, Maryland, OncoC4 is a privately-held, late-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment.

OncoC4 is a spinout of OncoImmune that was acquired by Merck in December 2020. OncoImmune was founded in 2000 on the scientific discoveries of our founders who have moved our lead product, CD24Fc, from a basic concept into clinical trials for multiple indications. As part of global effort to confront COVID-19, OncoImmune has also completed a Phase III clinical trial, SAC-COVID, which showed that CD24Fc significantly improved clinical recovery while reducing disease progression to death or respiratory failure.

As part of the acquisition of OncoImmune by Merck, OncoC4 retains the original assets except for the CD24Fc and was infused with additional funds from Merck to invigorate our product development pipeline focusing on best-in-class and first-in-class immunotherapies for oncology.

Our leading clinical candidate is ONC-392, a next generation anti-CTLA-4 antibody capable of uncoupling cancer therapeutic effect from immunotherapy-related adverse effect. A first-in-human Phase I clinical trial for ONC-392 was initiated in 2020 under OncoImmune and is currently enrolling cancer patients under OncoC4 sponsorship to assess the safety, pharmacokinetics, and efficacy of ONC-392 as a single agent in advanced solid tumors and in combination with anti-PD(L)1 standard of care in Non- Small Cell Lung Cancer (PRESERVE-001, NCT04140526).

In addition, OncoC4 has a pipeline of first-in-class immunotherapy products that are moving through preclinical testing.